Psychopharmacology

, Volume 232, Issue 16, pp 3091–3100

New onset executive function difficulties at menopause: a possible role for lisdexamfetamine

Authors

    • Department of PsychiatryPerelman School of Medicine at the University of Pennsylvania
    • Obstetrics and GynecologyPerelman School of Medicine at the University of Pennsylvania
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
  • Sheila Shanmugan
    • Department of PsychiatryPerelman School of Medicine at the University of Pennsylvania
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
  • Deborah R. Kim
    • Department of PsychiatryPerelman School of Medicine at the University of Pennsylvania
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
  • Sarah Mathews
    • Department of PsychiatryPerelman School of Medicine at the University of Pennsylvania
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
  • Kathryn A. Czarkowski
    • Department of PsychiatryPerelman School of Medicine at the University of Pennsylvania
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
  • Jeanette Bradley
    • Department of PsychiatryPerelman School of Medicine at the University of Pennsylvania
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
  • Dina H. Appleby
    • Department of PsychiatryPerelman School of Medicine at the University of Pennsylvania
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
  • Claudia Iannelli
    • Department of PsychiatryPerelman School of Medicine at the University of Pennsylvania
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
  • Mary D. Sammel
    • Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of Pennsylvania
    • Department of Epidemiology and BiostatisticsUniversity of Pennsylvania
  • Thomas E. Brown
    • Department of PsychiatryYale University School of Medicine
Original Investigation

DOI: 10.1007/s00213-015-3953-7

Cite this article as:
Epperson, C.N., Shanmugan, S., Kim, D.R. et al. Psychopharmacology (2015) 232: 3091. doi:10.1007/s00213-015-3953-7

Abstract

Rationale

Reports of cognitive decline, particularly in the domains of executive functions (EFs), are common among menopausal women.

Objective

This study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who report new-onset EF complaints.

Methods

Thirty-two healthy perimenopausal and early postmenopausal women experiencing mid-life-onset executive function difficulties as measured using the Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40–60 mg/day for 4 weeks in this double-blind, placebo-controlled, cross-over study. Diagnosis of lifetime ADHD was exclusionary. BADDS total and subscale scores and performance on verbal memory and working memory tasks were outcomes of interest.

Results

Analyses revealed a significant effect of LDX treatment over placebo for total BADDS scores (p = 0.0001) and for four out of the five BADDS subscales (all p < 0.004). LDX treatment also resulted in significant improvement in delayed paragraph recall (p = 0.018), but there was no significant effect of treatment on other cognitive measures. Systolic blood pressure (p = 0.017) and heart rate increased significantly (p = 0.006) when women were on LDX but remained, on average, within the normal range.

Conclusions

LDX 40–60 mg/day was well tolerated and improved the subjective measures of executive function as well as objective measures of delayed verbal recall in this sample of healthy menopausal women.

Keywords

Menopause Cognition Executive function ADHD Psychostimulant Lisdexamfetamine Brown Attention Deficit Disorder Scale Verbal memory Paragraph recall

Supplementary material

213_2015_3953_MOESM1_ESM.pdf (368 kb)
ESM 1 (PDF 368 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2015